Navigation Links
Monogram Announces 2008 Second Quarter Financial Results
Date:7/29/2008

al approach and products by pharmaceutical and biotechnology companies; our estimate of the size of our markets; our estimates of the levels of demand for our products; the impact of competition; the timing and ultimate size of pharmaceutical company clinical trials; whether payers will authorize reimbursement for our products and services and the amount of such reimbursement that may be allowed; whether the FDA or any other agency will decide to further regulate our products or services, including Trofile; whether existing levels of reimbursement will be reviewed and reduced by third party payers, including Medicare; whether the draft guidance on Multivariate Index Assays issued by FDA will be subsequently determined to apply to our current or planned products; whether we will encounter problems or delays in automating our processes; the ultimate validity and enforceability of our patent applications and patents; the possible infringement of the intellectual property of others; whether licenses to third party technology will be available; whether we are able to build brand loyalty and expand revenues; restrictions on the conduct of our business imposed by the Pfizer, G.E. and other debt agreements; the impact of additional dilution if our convertible debt is converted to equity; and whether we will be able to raise sufficient capital in the future, if required. For a discussion of other factors that may cause actual events to differ from those projected, please refer to our most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission. We do not undertake, and specifically disclaim any obligation, to revise any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements.

PhenoSense, PhenoSenseGT, Trofile, HERmark and VeraTag are trademarks of Monogram Biosciences, Inc. Hercept
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. Monogram Announces First Medicare Payment for Trofile(TM)
2. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
3. Monogram Biosciences Announces Immediate Availability of Enhanced Sensitivity Trofile(TM) HIV Tropism Assay
4. Monogram Biosciences Collaborates with Gilead Sciences for Elvitegravir Phase III Studies
5. Monogram Announces Commercial Availability of the HERmark(TM) Breast Cancer Assay
6. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
7. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
8. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
9. HEI, Inc. Announces Sale of RFID Division Assets
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
11. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)... New York, New York (PRWEB) August 30, 2014 ... and other incretin mimetic claims continue to move forward ... a statement issued by AstraZeneca PLC on July 31, ... have been named in 409 product liability claims that ... cancer. Court documents indicate that many of these claims ...
(Date:8/30/2014)... 2014 Hastings and Hastings, a qualified ... throughout Arizona is pleased to report having saved a ... example among many cases where Hastings and Hastings has ... retain a greater portion of their settlement or recovery. ... a positive solution for Arizona car accident victims is ...
(Date:8/30/2014)... New York (PRWEB) August 30, 2014 ... development company in India, Profit By Outsourcing is ... Web Development services. The company gives emphasize on putting ... the complete product to clients. Their dedicated team of ... attaining ground-breaking results. They can handle even the critical ...
(Date:8/30/2014)... In today’s world, a good night’s sleep has ... sleep apnea (a medical problem where the airway collapses during ... of the rest they need to face their daily challenges. ... 20 million people in the United States alone have sleep ... and of those treated, many cannot tolerate their prescribed medical ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 Removecomplaints.net, a ... management industry, has announced to offer guarantee of results ... to offer this guarantee because of its tremendous track ... 200 clients from all over the world and received ... good job. , On being asked about the ...
Breaking Medicine News(10 mins):Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $67,100 On A Settlement Of $610,000 2Health News:Profit By Outsourcing Offering Discount for Labor Day on all Web Development Services 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Removecomplaints.net Announces Guaranteed Complaints Removal Services 2
... associated with loss of blood supply to the brain , , ... type of depression in the elderly related to blood vessels ... have discovered why some patients with this condition fail to ... to be presented Wednesday during a news conference by researchers ...
... million, up 20% from first quarter ... - EPS of $0.38, up 36% from first quarter 2007, - Record new ... 2007, ... ...
... been made in reducing the harm of tobacco in ... ... Tomorrow marks the 10-year,anniversary of Minnesota,s historic settlement with the ... national headlines for,exposing millions of tobacco industry documents and for creating ...
... MELVILLE, N.Y., May 6 Today, Fougera, ... has received FDA approval to bring to ... (Rx) (Scalp,Solution). The generic formulation compares to ... ), Fougera,s Calcipotriene Topical Solution is ...
... Calif., May 6 Capitol Chiropractic,Buckle-Up Safe Day 2008 will ... noon and 3:30 p.m. to 6:30 p.m. at 9500 Micron ... great way to help prevent and/or reduce,car crash injuries to ... way of giving back to our community, through teaching simple ...
... Open Course in Celebrity Foursome, WASHINGTON, May 6 ... cancer survivor, John,Atkinson has won the Golf Digest U.S. ... over 56,000 entries., He will try to break ... the,pros for this year,s U.S. Open. Atkinson will compete ...
Cached Medicine News:Health News:Several Therapies Show Promise for Vascular Depression 2Health News:Several Therapies Show Promise for Vascular Depression 3Health News:Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008 2Health News:Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008 3Health News:Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008 4Health News:Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008 5Health News:Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008 6Health News:Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008 7Health News:ClearWay Minnesota(SM) Celebrates 10-Year Anniversary of Settlement 2Health News:Fougera First-to-Market With Calcipotriene Topical Solution 0.005% (Rx) (Scalp Solution) 2Health News:Sacramento Chiropractor Takes Aim at Reducing Car Accident Injuries 2Health News:Lung Cancer Alliance Advocate Wins Golf Digest Contest 2
(Date:8/29/2014)... 29, 2014 Research and Markets ... Instrument Industry Report, 2014-2017" report to their offering. ... rising proportion of reimbursement for medical expenses, the Chinese ... its scale presenting a CAGR of 19.2% during 2009-2013. ... product segments of orthopedic instruments in China ...
(Date:8/29/2014)... Research and Markets  has announced the addition of the ... to their offering. The Central Nervous System ... segments of pharmaceuticals industry. The numbers of CNS disorders have ... unable to meet the market requirements. There has been steady ... over the past two decades. The market for CNS therapies ...
(Date:8/29/2014)... your doctor know what you,re smoking?  Chances are, probably not.  ... over 112,000 currently registered patients under Colorado,s ... 20,300+ active physicians listed with the Colorado Dept of Regulatory ... a poll in February 2014 showed 51% of ... "With marijuana legalization underway, every doctor needs a ...
Breaking Medicine Technology:China Orthopedic Instrument Industry Report, 2014-2017 2US CNS Disorders Drug Pipeline Insight 2014 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4
... in Patients Following Bunionectomy, TAMPA, Fla., May ... several days following removal of a,bunion, one of ... tapentadol provided significant relief for patients who had ... with tapentadol,also resulted in patients reporting fewer gastrointestinal ...
... X-ray ... Data -, ... two-year Phase III study showing that ACTEMRA(TM),(tocilizumab) can significantly inhibit progression of ... of,effectiveness of an RA treatment. The study also demonstrated that ACTEMRA,reduces disease ...
Cached Medicine Technology:New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery 2New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery 3New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery 4New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery 5New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 2New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 3New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 4New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 5
... The Stockert 70 RF ... the EP lab every day, ... the Stockert 70 and the ... NAVI-STAR Diagnostic/Temperature Ablation Catheter provide ...
The Regency family of pacemakers offers advanced, easy-to-use rate-responsive and nonrate-responsive devices....
... The Identity pacemaker family, ... dual-chamber pacemaker, provides clinicians with ... available, including the revolutionary AF ... only U.S. commercially approved algorithm ...
... Frontier II device is designed ... moderate to severe heart failure ... in patients who are symptomatic ... and who have prolonged QRS ...
Medicine Products: